Clinical Trials

BreastDermatologicGastrointestinalGenitourinaryGynecologic

77 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04739670 2024-03-01

BELLA

31 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT03818685 2024-02-12

BreastImmune03

95 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

49 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04914390 2024-01-22

NeoATCT

32 enrolled

Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

139 enrolled

Triple Negative Breast Neoplasms

NCT03812393 2023-12-18

FACT-2

27 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06154109 2023-12-01

Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial

90 enrolled

Triple Negative Breast Neoplasms

NCT04734262 2023-11-18

SPARK

98 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05498597 2023-10-19

AMT-151 in Patients With Selected Advanced Solid Tumours

BreastGynecologicOther solid neoplasmThoracic

30 enrolled

Adenocarcinoma of Lung, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Carcinoma, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05174832 2023-09-28

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

136 enrolled

Triple Negative Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT05957939 2023-07-24

Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial

2 enrolled

Triple Negative Breast Neoplasms

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

125 enrolled

Triple Negative Breast Neoplasms

NCT03920488 2023-06-28

PERSONA

264 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05910710 2023-06-20

Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

50 enrolled

Triple Negative Breast Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

65 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05302778 2023-05-25

HERMIONE-10

200 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05872412 2023-05-25

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

82 enrolled

Triple Negative Breast Neoplasms

NCT05831553 2023-05-06

TIP

Triple Negative Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

58 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

45 enrolled

Triple Negative Breast Neoplasms

NCT04365790 2023-03-08

Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03475953 2023-03-03

REGOMUNE

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

747 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT05670925 2023-02-28

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

46 enrolled

Triple Negative Breast Neoplasms

NCT05453825 2023-01-31

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

BreastGastrointestinalGynecologic

180 enrolled

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05692661 2023-01-20

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

24 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04248998 2023-01-18

BREAKFAST

30 enrolled

Phase EARLY_PHASE1 Unknown

Triple Negative Breast Neoplasms

NCT05680662 2023-01-11

The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism

200 enrolled

Triple Negative Breast Neoplasms

NCT05390476 2022-11-04

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

126 enrolled

Triple Negative Breast Neoplasms

NCT03907800 2022-10-27

NeoPATH

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

40 enrolled

Triple Negative Breast Neoplasms

NCT03720431 2022-08-17

TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

11 enrolled

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

140 enrolled

Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04297267 2022-07-22

nonpCR GP

Triple Negative Breast Neoplasms

NCT05461690 2022-07-18

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

50 enrolled

Triple Negative Breast Neoplasms

NCT04460456 2022-06-30

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

58 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

70 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05303038 2022-06-09

Castle06(BC)

15 enrolled

Triple Negative Breast Neoplasms

NCT05402722 2022-06-02

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT02341911 2022-04-20

TNBC

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03251313 2022-04-20

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

31 enrolled

Triple Negative Breast Neoplasms

NCT04192903 2022-04-20

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

55 enrolled

Triple Negative Breast Neoplasms

NCT04609215 2022-04-20

ImmunoBreast - A Phase Ib Study

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04634747 2022-04-20

Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

53 enrolled

Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT04457700 2022-04-18

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

218 enrolled

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02637531 2022-04-04

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549